1. Pretreatment of female rats with (-)-emetine or (±)-2,3-dehydroemetine (at 18,umol/kg body wt. for 24h) prolongs the hexobarbital-induced sleeping-time of the treated animals. 2. This effect is not observed on pretreating animals with other compounds closely related to (-)-emetine, such as (-)-isoemetine or (+)-O-methylpsychotrine. 3. Liver microsomal drug-metabolizing enzyme activity in vitro as measured by N-demethylation of aminopyrine and azo-reduction of Neoprontosil is inhibited in rats pretreated with (-)-emetine or with (±)-2,3-dehydroemetine. 4. These inhibitory effects on drug metabolism in vitro are not observed in corresponding experiments involving pretreatment of rats with (-)-isoemetine or (+)-O-methylpsychotrine. 5. Co-administration of emetine or 2,3-dehydroemetine and sodium phenobarbital or 1,1-dichloro-2-o-chlorophenyl-2-p-chlorophenylethane to rats abolishes or greatly diminishes the stimulation of drug-metabolizing enzyme activity in vitro usually obtained by the administration of phenobarbital or 1,1-dichloro-2-o-chlorophenyl-2-p-chlorophenylethane alone. 6. Further, in rats pretreated with sodium phenobarbital and subsequently injected with emetine or 2,3-dehydroemetine the pre-stimulated drug-metabolizing enzyme activity in vitro is diminished. 7. The inhibitory effects on drug-metabolizing enzyme activity after pretreatment with (-)-emetine or (+)-2,3-dehydroemetine do not appear to be related to NADPH generation.
18,umol/kg body wt. for 24h) prolongs the hexobarbital-induced sleeping-time of the treated animals. 2. This effect is not observed on pretreating animals with other compounds closely related to (-)-emetine, such as (-)-isoemetine or (+)-O-methylpsychotrine. 3. Liver microsomal drug-metabolizing enzyme activity in vitro as measured by N-demethylation of aminopyrine and azo-reduction of Neoprontosil is inhibited in rats pretreated with (-)-emetine or with (±)-2,3-dehydroemetine. 4. These inhibitory effects on drug metabolism in vitro are not observed in corresponding experiments involving pretreatment of rats with (-)-isoemetine or (+)-O-methylpsychotrine. 5. Co-administration of emetine or 2,3-dehydroemetine and sodium phenobarbital or 1,1-dichloro-2-o-chlorophenyl-2-p-chlorophenylethane to rats abolishes or greatly diminishes the stimulation of drug-metabolizing enzyme activity in vitro usually obtained by the administration of phenobarbital or 1,1-dichloro-2-o-chlorophenyl-2-p-chlorophenylethane alone. 6. Further, in rats pretreated with sodium phenobarbital and subsequently injected with emetine or 2,3-dehydroemetine the pre-stimulated drug-metabolizing enzyme activity in vitro is diminished. 7. The inhibitory effects on drug-metabolizing enzyme activity after pretreatment with (-)-emetine or (+)-2,3-dehydroemetine do not appear to be related to NADPH generation.
Liver microsomal preparations obtained from rats pretreated with sodium phenobarbital have a greater capacity than the corresponding control preparations for incorporating labelled amino acid into protein in vitro (Kato, Jondorf, Loeb, Ben & Gelboin, 1966) . The liver microsomal stimulation of protein-synthesizing activity after treatment with phenobarbital is also associated with increased liver microsomal drug-metabolizing enzyme activity in vitro (Conney, 1967) . In similar experiments involving (-)-emetine (Jondorf & Szapary, 1968) or (±)-2,3-dehydroemetine (Jondorf, Drassner, Johnson & Miller, 1969a) , liver microsomal preparations isolated from rats pretreated with these compounds had greatly enhanced amino acid-incorporating activities in vitro compared with the controls at 24h after pretreatment. At this time point, as already briefly reported (Jondorf, Johnson & Drassner, 1969b; Jondorf, Johnson & Donahue, 1969c) , pretreatment with emetine or 2,3-dehydroemetine exerted an inhibiting effect on drug-metabolizing enzyme activity in liver microsomal preparations in vitro. We therefore tested whether co-administration to rats of an inducer of drug-metabolizing enzyme activity, such as phenobarbital, and an inhibitor, such as emetine or 2,3-dehydroemetine, would lead to an overall inhibition of drug-metabolizing activity as measured in vitro by using aminopyrine (Jondorf, Simon & Avnimelech, 1966) and Neoprontosil (Hernandez, Gillette & Mazel, 1967) as substrates. We further tested emetine and 2,3-dehydroemetine inhibitory effects against a different type of inducer, o,p'-DDD* (Boyland & Jondorf, 1962; Straw, Waters & Fregly, 1965; Kupfer & Peets, 1966) , to see whether the emetine type of compound could neutralize the stimulating effects on drug-metabolizing activity brought about by other drugs used in human therapy.
We also set out to determine whether structureactivity relationships among emetine derivatives that had been established for anti-amoebic activity and for effects exerted by these compounds on protein synthesis (Grollman, 1966; Jondorf et al. 1969a ) were valid for inhibitory effects observed on drug-metabolizing enzyme activity in the rat. The active centre of the emetine molecule (Grollman, 1966 ) is thought to involve the correct stereospecific alignment at C-i' and a secondary amine structure at N-2'.
for comparison with emetine and 2,3-dehydroemetine ( Fig. 1) for this purpose. The results obtained by studying effects on drug metabolism taken in conjunction with previous studies using N-methylemetine (Jondorf, Johnson & Donahue, 1969d) are consistent with the suggestion that the 'active centre' determining biological potency of the emetine molecule involves the correct stereochemical alignment at the asymmetric carbon atom in the I'-position in the molecule, and a free secondary amine structure at the 2'-position (Grollman, 1966) . (Jondorf & Szapary, 1968) , 2,3-dehydroemetine (Jondorf et al. 1969a (Diamant, 1958 (Hogeboom, 1955) at 600g (lOmin), 15000g (15min) and 105000g (60min) at 0-40C, for the preparation of microsomal pellets and i050Og supernatant fractions. The microsomal pellets were rinsed several times with fresh ice-cold homogenization medium and were then carefully redispersed in this medium so that 0.4ml of the opalescent microsomal solution was equivalent to 0.375g wet wt. of liver. The microsomal preparations obtained in this way were used in combination with 105OOOg supernatant preparations (also equivalent to 0.375g wet wt. of liver) from control rats, for the assay ofdrug-metabolizing activity in vitro as indicated below. The subcellular materials were always used on the day of preparation.
Drug-metabolizing enzyme activity in vitro. For measuring the oxidative N-demethylation of aminopyrine, microsomal fractions from pretreated or control livers equivalent to 0.375g wet wt. of liver were incubated aerobically, in duplicate, in a shaking water bath at 370C for 30min with 105000g control supernatant preparation also equivalent to 0.375g of liver, 2.5,umol of aminopyrine, and a complete supporting system ) and semicarbazide to react with any formaldehyde formed metabolically. Reactions were stopped with equal volumes (4.5ml) of saturated lead subacetate solution. Subsequently the precipitated protein was removed by centrifugation and portions of the clear supernatant material were aspirated and assayed for formaldehyde by the Cochin & Axelrod (1959) modification of the Nash (1957) method. Recoveries, tissue blanks and protein concentration (Lowry, Rosebrough, Farr & Randall, 1951) were determined for each preparation so that the results could be expressed as net average values for formaldehyde formed (in nmol)/mg of microsomal protein in 30min. Bovine serum albumin fraction V (Armour Pharmaceutical Co., Kankakee, Ill., U.S.A.) served as the standard in all protein determinations.
For measuring the azo-reduction of Neoprontosil, microsomal preparations from livers of pretreated or control rats were incubated with control 105000g hepatic supernatant material (equivalent to 0.375g wet wt. of liver) in duplicate, in the shaking water bath at 37°C under an atmosphere of 02-free N2 with 10umol of substrate and the complete supporting system of Hernandez et al. (1967) . Reactions were stopped after 30min with equal volumes (5.Oml) of ice-cold 10% (w/v) trichloroacetic acid. After centrifugation, the sulphanilamide formed as a metabolite from Neoprontosil was separated by column chromatography (Hernandez et al. 1967 ) of the deproteinized supernatant material and was then assayed by diazotization and coupling with N-(1-naphthyl)ethylenediamine (Bratton & Marshall, 1939) . All results quoted in the Results section are net average values calculated from duplicate incubations, based on microsomal protein content and corrected for non-enzymic azo-reduction of Neoprontosil, and for sulphanilamide recoveries.
Reduction of NADP+ in the support 8y8tem for the drugmetabolizing in vitro. The formation of NADPH was measured by the method of Horecker & Kornberg (1957) by using the 105000g supernatant fraction from normal untreated rat liver as the source ofthe glucose 6-phosphate dehydrogenase enzyme. Reaction mixtures contained the following components in total volumes of 3.0ml: 0.04M-glycylglycine buffer, pH7.5, 0.5ml; 0.lx-MgCI2, 0.3ml; 1,um-NADP+ in 0.3ml of buffer; 0.02M-glucose 6-phosphate, 0.1ml; 105000g supernatant fraction, 0.1ml; water, 1.7ml or 1.4ml depending on whether (±)-2,3-dehydroemetine in various amounts (in 0.3ml) of buffer was added to the system. The formation of NADPH was observed by reading the El I value in quartz cuvettes at various time-points at 37°C in a thermostatically controlled Beckman DU u.v. spectrophotometer with a Gilford model 2000 attachment. Protein determinations (Lowry et al. 1951 ) of the supernatant fractions were performed so that the results could be expressed as pmol of NADPH/min per mg of protein.
Drug-metabolizing activity in vivo. The time-interval between the loss and the return of the righting reflex after treatment of animals with sodium hexobarbital (Quinn, Axelrod Brodie, Maickel & Jondorf, 1958) is recognized as an indicator of hepatic drug-metabolizing activity in vivo. Alterations in the duration of the hexobarbital-induced sleeping-time may be brought about by pretreatment of animals with other drugs. These altera. tions can be related to changes in drug-metabolizing enzyme activity, if it is assumed that the pretreatment does not sensitize the animals to the barbiturate in any way.
Groups of ten carefully matched female SpragueDawley rats (50g body wt.), of the same age from the same breeder, were injected intraperitoneally with water or with emetine (or one of its related compounds) at a dosage of 18,umol/kg body wt. The injection volume (0.5ml/50g rat) was intended to minimize error through leakage at the site of injection. All rats were starved for 24 h before they were treated intraperitoneally with sodium hexobarbital in freshly made aqueous solution (388,umol/kg, i.e. 100mg/kg body wt.). The duration of the loss of the righting reflex was then measured for the various groups of animals.
RESULTS
Compariwon of effects due to pretreatment with various compounds related to emetine in vivo on liver mwcrosomal drug metaboli8m in vitro. On incubating the liver microsomal fractions prepared from groups of two rats pretreated for 24h with emetine or one of its derivatives, with 105 OOOg supernatant fraction obtained from the livers of control animals, and substrates for measuring oxidative N-demethylation or azo-reduction, as outlined in the Methods section, we obtained the results shown in Table 1 . It is evident that pretreatment with either emetine or 2,3-dehydroemetine at 18,umol/kg for 24h exerts an inhibiting effect of about 50% on drug-metabolizing enzyme activity in vitro. However, pretreatment of rats with isoemetine or O-methylpsychotrine had no such inhibiting effect in vitro on demethylation of aminopyrine or azoreduction of Neoprontosil by the liver microsomal fractions subsequently prepared from animals given injections with these other compounds related to emetine. Even when the rats were pre-injected with doses of isoemetine or O-methylpsychotrine as high as 144,umol/kg there was no noticeable inhibitory effect on drug-metabolizing enzyme activity in vitro as measured by N-demethylation and azo-reduction.
Influence of pretreatment with emetine or related compounds on drug metabolism in vivo as measured by duration of the hexobarbital-induced sleeping-time. Kale, Joglekar & Balwani (1966) showed that emetine pretreatment would prolong the hexo.-barbital-induced loss of righting reflex in rats, and decrease their ascorbic acid synthesis as measured by urinary excretion. Both of these are parameters of decreased liver microsomal drug-metabolizing enzyme activity (Quinn et al. 1958; Conney & Burns, 1959) . Table 2 shows the effects of sodium hexobarbital administration (100mg/kg) on the average sleeping-times of groups of ten carefully selected (Grollman, 1966; Jondorf et al. 1969a ). Effect of 2,3-dehydroemetine on the reduction of NADP+ by glucose 6-phosphate dehydrogenase. A study by Watkins & Guess (1968) on the inhibitory effect exerted by emetine on oxidative phosphorylation in isolated embryonic chick heart cells suggested that emetine inhibited the formation of NADH from NAD+. This implied that emetine inhibited a dehydrogenase. If this were true, then, by analogy, the effects exerted by emetine or 2,3-dehydroemetine on NADPH-dependent drugmetabolizing enzyme activity (Gillette, Brodie & La Du, 1957) might be explained by inhibition of glucose 6-phosphate dehydrogenase-mediated formation of NADPH from NADP+.
However, as indicated in Table 3 , the addition of various amounts of 2,3-dehydroemetine to the control hepatic 105OO0g supernatant fraction used in the drug-metabolizing experiments in vitro as the source for glucose 6-phosphate dehydrogenase has no effect on the generation ofNADPH from NADP+. Similar results were obtained with emetine.
We conclude from this that the inhibitory effects (Miller & Jondorf, 1970 Co-administration of sodium phenobarbital and emetine or 2,3-dehydroemetine. Table 5 shows the effects on liver microsomal N-demethylation of aminopyrine in vitro brought about by pretreatment of rats with sodium phenobarbital and emetine or 2,3-dehydroemetine alone or in combination. The results refer to different injection schedules, which were devised to try and differentiate between effects exerted by emetine or 2,3-dehydroemetine on (-59%) incipient stimulation of drug-metabolizing activity by phenobarbital, and on already existing phenobarbital-induced stimulation of N-demethylating activity.
In the type of experiment where animals are treated with phenobarbital for 1 day, the co-ENZYME INHIBITION BY EMETINE Vol. 117 495 administration of emetine or 2,3-dehydroemetine blocks the incipient stimulation ofN-demethylating activity. Emetine or 2,3-dehydroemetine alone, as we have shown above (Table 1) , inhibits drugmetabolizing activity in this type of 1-day experiment by about 50%.
When animals are pretreated with phenobarbital daily for 3 days, much greater stimulation of liver microsomal drug-metabolizing activity is observed, as expected. This stimulation of N-demethylating activity is diminished but not eliminated in rats where emetine or 2,3-dehydroemetine are coadministered with phenobarbital on the third day of the phenobarbital treatment. Both emetine and 2,3-dehydroemetine exert inhibiting effects on the drug-metabolizing enzyme activity as measured by formaldehyde formation from aminopyrine in vitro, even in preparations from animals that were prestimulated with phenobarbital.
Thepatternisessentially similarfor azo-reduction, as measured by the enzymic formation of sulphanilamide from Neoprontosil in liver microsomal incubations in vitro. The stimulation brought about by phenobarbital by 1-day pretreatment with phenobarbital is not so great in terms of percentage increase, but the co-administration of emetine or 2,3-dehydroemetine blocks the incipient stimulating effect on azo-reduction by phenobarbital and decreases this activity to values below that of the control. Emetine or 2,3-dehydroemetine alone inhibits sulphanilamide formation from Neoprontosil by about 50 % (see Table 1 ). With 3 days of phenobarbital treatment there is a greater stimulation of azo-reduction than at 1 day. The pre-stimulated animals respond to emetine or 2,3-dehydroemetine co-administered with phenobarbital on the third day, and the phenobarbital effects are diminished by over 50%. (Woolfe, 1963 (Woolfe, , 1965 and may find use in the treatment of certain antifolatesensitive leukaemias (Jondorf, 1969 (Grollman, 1966 (Grollman, , 1968 Jondorf & Szapary, 1968; Jondorf et al. 1969a) . Previous studies on the tissue distribution of emetine in rabbits (Parmer & Cottrill, 1949) , guinea-pigs (Schwartz & Herrero, 1965) and rats (Gimble, Davison & Smith, 1948; Davis, Dodds & Tomich, 1962) indicated that emetine was retained in some tissues for considerable periods of time, and was not excreted to any appreciable extent in the urine (Gimble etal. 1948; Schwartz & Herrero, 1965) . This suggested that emetine might not be metabolited. In this connexion, Kale et at. (1966) have found that emetine had some inhibiting effects on certain parameters of liver microsomal drugmetabolizing enzyme activity. We have been able to confirm that emetine is not metabolized by O-demethylation in a rat liver microsomal drugmetabolizing system in vitro (Jondorf et al. 1969d ), and we have already briefly reported that both emetine and 2,3-dehydroemetine inhibit drugmetabolizing activity in vitro by liver microsomal preparations from animals pretreated with either of these compounds (Jondorf et al. 1969b,c) .
We have now shown that liver microsomal drug-metabolizing enzyme activity, as measured by N-demethylation of aminopyrine and azo-reduction of Neoprontosil in vitro, and duration of hexobarbital-induced sleeping time in vivo, is inhibited in rats pretreated with (-)-emetine or (+)-dehydroemetine at 18,umol/kg for 24h. In corresponding experiments with rats pretreated with (-)-isoemetine or (±)-O-methylpsychotrine ( Fig. 1) at the same dosage and for the same period of time, no inhibitory effects on liver microsomal drug-metabolizing enzyme activity were observed (Tables 1 and 2) . Further, no changes in drug-metabolizing activity were noted in animals that had received isoemetine or O-methylpsychotrine at a pretreatment dosage of 144,umol/kg, which would be well within the lethal range for emetine (Jondorf & Szapary, 1968) or 2,3-dehydroemetine (Jondorf et al. 1969a ). We conclude from this that structure-activity relationship among derivatives of emetine, first suggested by Grollman (1966) in connexion with his studies on amoebicidal effects and inhibition of protein synthesis in vitro, are also consistent with the degree of effectiveness in inhibiting the rat liver microsomal drug-metabolizing systems. According to Grollman (1966) , the structural requirements for amoebicidal activity and inhibitory effects on protein synthesis in compounds related to emetine are first, the correct stereospecific alignments at the asymmetric C-l' position ( Fig. 1) and an unsubstituted secondary amine at the N-2' position in the molecule. Naturally-occurring emetine and synthetic 2,3-dehydroemetine satisfy these requirements. Both compounds are active in Groilman's (1966) systems. On the other hand, isoemetine lacks the correct configuration at C-l', and in the O-methylpsychotrine molecule C-l' is no longer a centre of asymmetry, nor is the nitrogen at the 2'-position a secondary amine (Fig. 1) . Neither isoemetine nor O-methylpsychotrine is an effective inhibitor of protein synthesis (Groilman, 1966) . In our own previous studies on the comparative effects exerted by various compounds related to emetine on some parameters of protein biosynthesis in rat liver (Jondorf & Szapary, 1968; Jondorf et al. 1969a,d) we found that pretreatment of rats with emetine, 2,3-dehydroemetine or cephaeline at 18,umol/kg had a stimulatory effect on the amino acid-incorporating activity in vitro of liver microsomal fractions prepared from the treated rats 24h later. Under these conditions isoemetine and O-methylpsychotrine had no effect on proteinsynthesizing activity of the rat liver microsomal system (Jondorf et al. 1969a) . N-Methylemetine pretreatment had some intermediate stimulatory effect on the protein-synthesizing system (Jondorf et al. 1969d) , which demonstrated that the requirement for a free secondary amine structure at the 2'-position (Grollman, 1966) , though important, was not quite so decisive as the correct configuration at the l'-position.
It is not altogether unexpected that isoemetine and O-methylpsychotrine would be inactive as inhibitors of drug-metabolizing activity in the rat. What is surprising, however, is that the biochemically active compounds should exert inhibitory effects on drug-metabolizing activity andyetstimulate amino acid-incorporating activity at the liver microsomal level in the rat, at the same dosage and at the same time-interval after pretreatment. We have previously noted such divergent microsomal effects in rats after pretreatment with cycloheximide or related glutarimide antibiotics (Miller, Johnson, Donahue & Jondorf, 1969) .
In trying to explain the mechanism of the inhibitory effects on drug-metabolizing enzyme activity, we examined the effects of adding 2,3-dehydroemetine directly to the N-demethylating system in vitro (R. K. Johnson, P. Mazel, J. D. Donahue & W. R. Jondorf, unpublished work). Under these conditions there is a concentrationdependent inhibition of N-demethylation of aminopyrine. However, on pretreatment of female Sprague-Dawley rats with 2,3-dehydroemetine at 18,umol/kg for 24h and measuring the subcellular distribution of this compound in the liver (Miller & Jondorf, 1970) , we find that the amounts of drug associated with the combined microsomal and 105 OOOg supernatant fractions equivalent to 0.375g of liver used in the assays here are too minute to explain any inhibitory effects on drug metabolism.
Another possibility arose from a consideration of the work of Appelt & Heim (1965) , who had shown that emetine inhibited the NADW-dependent oxidation of substrates by rat heart homogenates without marked interference in the rate of NAD+ synthesis. Similarly, Watkins & Guess (1968) had suggested that emetine inhibited NADH formation, thus uncoupling oxidative phosphorylation and decreasing ATP production in embryonic chick heart. It was conceivable that the inhibitory effects on drug-metabolizing activity in rat liver might be due to some emetine-or 2,3-dehydroemetine-linked inhibition of glucose 6-phosphate dehydrogenasedependent generation of NADPH from NADP+. However, as shown in Table 3 , this is not the case, and the inhibitory effects exerted by 2,3-dehydroemetine or emetine are not connected with the impaired generation of the NADPH-cofactor required for drug metabolism in vitro (Gillette et al. 1957; Brodie, Gillette & La Du, 1958) .
With respect to the combined pretreatment of rats with compounds related to emetine and drugs such as o,p'-DDD (Boyland & Jondorf, 1962; Straw et al. 1965; Kupfer & Peets, 1966) or sodium phenobarbital (Gillette, 1963; Conney, 1967) , known to stimulate drug-metabolizing enzyme activity, we find that emetine and 2,3-dehydroemetine each prevent the expected enhancement of drug-metabolizing enzyme activity at the liver microsomal level in vitro (Tables 4, 5) . Under the appropriate circumstances these anti-amoebic drugs not only prevent the stimulation of the drugmetabolizing enzymes but inhibit pre-existing stimulation of the drug-metabolizing activity by liver microsomes (Table 5) .
These would appear to be very important effects in view of the large number of drugs and environmental factors known to stimulate drug metabolism in various species (Conney, 1967) . Inhibitors ofdrug metabolism are relatively rare (Netter, 1961; Gillette, 1963) and the knowledge that emetine and 2,3-dehydroemetine can inhibit liver microsomal drug-metabolizingenzymeactivitywillundoubtedly prove useful with regard to the molecular pharmacology of microsomal drug metabolism since the 'active centre' of the emetine molecule is known (Grollman, 1966; Jondorf et al. 1969a) , and this ought to provide a further stimulus for studying the enzymic site of the inhibition.
